Immunovant (IMVT) EBT (2018 - 2026)

Immunovant has reported EBT for 9 years, with the latest figure at -$150.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 42.35% year-over-year to -$150.7 million; the trailing twelve-month figure through Mar 2026 stood at -$505.4 million (down 22.39% YoY), and the FY2026 full-year result was -$505.4 million, down 22.39% from the prior year.
• EBT for Q1 2026 stood at -$150.7 million, down from -$109.1 million in the prior quarter.
• The five-year high for EBT was -$40.0 million in Q2 2022, with the low at -$150.7 million in Q1 2026.
• Historically, EBT has averaged -$84.4 million across 5 years, with a median of -$75.1 million in 2024.
• Annual changes were most pronounced in 2023 — EBT advanced 18.0% — and 2024, when it slumped 115.37%.
• Immunovant's EBT stood at -$62.8 million in 2022, then rose by 18.0% to -$51.5 million in 2023, then tumbled by 115.37% to -$111.0 million in 2024, then rose by 1.7% to -$109.1 million in 2025, then plunged by 38.15% to -$150.7 million in 2026.
• The last three EBT figures came in at -$150.7 million (Q1 2026), -$109.1 million (Q4 2025), and -$125.9 million (Q3 2025), per Business Quant data.